Biomarkers of Response to Preoperative Chemoradiation in Esophageal Cancers

Seminars in Oncology

Volumn 33, Issue SUPPL. 11, 2006, Pages 2-5

  Luthra, Rajyalakshmi ^a   Luthra, Madan G ^a   Izzo, Julie ^a   Wu, Tsung Teh ^a   Lopez Alvarez, Enrique ^a   Malhotra, Usha ^a   Choi, In Seon ^a   Zhang, Li ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN; PROTEIN PERP; PROTEIN S100A2; PROTEIN SPRR3; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ARTICLE; BARRETT ESOPHAGUS; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CELL SURVIVAL; DNA MICROARRAY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; METASTASIS; POLYMERASE CHAIN REACTION; PRECANCER; PREOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR BIOPSY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RADIOTHERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 33845434783     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.10.004     Document Type: Article

References (40)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Ilson D.H. Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev 29 (2003) 525-532
3. Enzinger P.C., and Mayer R.J. Esophageal cancer. N Engl J Med 349 (2003) 2241-2252
4. Pera M. Recent changes in the epidemiology of esophageal cancer. Surg Oncol 10 (2001) 81-90
5. Bollschweiler E., Wolfgarten E., Gutschow C., et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92 (2001) 549-555
6. Wild C.P., and Hardie L.J. Reflux, Barrett's oesophagus and adenocarcinoma: Burning questions. Nat Rev Cancer 3 (2003) 676-684
7. Winters Jr. C., Spurling T.J., Chobanian S.J., et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 92 (1987) 118-124
8. Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg 27 (2003) 999-1008
9. Cameron A.J., Ott B.J., and Payne W.S. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 313 (1985) 857-859
10. Robertson C.S., Mayberry J.F., Nicholson D.A., et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 75 (1988) 760-763
11. Hameeteman W., Tytgat G.N., Houthoff H.J., et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 96 (1989) 1249-1256
12. Oberg S., Wenner J., Johansson J., et al. Barrett's esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 242 (2005) 49-54
13. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
14. Chaves P., Pereira A.D., Pinto A., et al. p53 protein immunoexpression in esophageal squamous cell carcinoma and adjacent epithelium. J Surg Oncol 65 (1997) 3-9
15. Casson A.G., Manolopoulos B., Troster M., et al. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Am J Surg 167 (1994) 52-57
16. Yokota J., Yamamoto T., Toyoshima K., et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1 (1986) 765-767
17. Chirieac L.R., Swisher S.G., Ajani J.A., et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103 (2005) 1347-1355
18. Rohatgi P.R., Swisher S.G., Correa A.M., et al. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 106 (2006) 552-558
19. Berger A.C., Farma J., Scott W.J., et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23 (2005) 4330-4337
20. Darnton S.J., Archer V.R., Stocken D.D., et al. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol 21 (2003) 4009-4015
21. Lu J., Liu Z., Xiong M., et al. Gene expression profile changes in initiation and progression of squamous cell carcinoma of esophagus. Int J Cancer 91 (2001) 288-294
22. Xu Y., Selaru F.M., Yin J., et al. Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett's esophagus and esophageal cancer. Cancer Res 62 (2002) 3493-3497
23. Xu S.H., Qian L.J., Mou H.Z., et al. Difference of gene expression profiles between esophageal carcinoma and its pericancerous epithelium by gene chip. World J Gastroenterol 9 (2003) 417-422
24. Hourihan R.N., O'Sullivan G.C., and Morgan J.G. Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues. Anticancer Res 23 (2003) 161-165
25. Zhou J., Zhao L.Q., Xiong M.M., et al. Gene expression profiles at different stages of human esophageal squamous cell carcinoma. World J Gastroenterol 9 (2003) 9-15
26. Ishibashi Y., Hanyu N., Nakada K., et al. Profiling gene expression ratios of paired cancerous and normal tissue predicts relapse of esophageal squamous cell carcinoma. Cancer Res 63 (2003) 5159-5164
27. Dahlberg P.S., Ferrin L.F., Grindle S.M., et al. Gene expression profiles in esophageal adenocarcinoma. Ann Thorac Surg 77 (2004) 1008-1015
28. McManus D.T., Olaru A., and Meltzer S.J. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 64 (2004) 1561-1569
29. Luo A., Kong J., Hu G., et al. Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene 23 (2004) 1291-1299
30. Kazemi-Noureini S., Colonna-Romano S., Ziaee A.A., et al. Differential gene expression between squamous cell carcinoma of esophageus and its normal epithelium; altered pattern of mal, akr1c2, and rab11a expression. World J Gastroenterol 10 (2004) 1716-1721
31. Brabender J., Marjoram P., Salonga D., et al. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. Oncogene 23 (2004) 4780-4788
32. Luthra R., Wu T.T., Luthra M.G., et al. Gene expression profiling of localized esophageal carcinomas: Association with pathologic response to preoperative chemoradiation. J Clin Oncol 24 (2006) 259-267
33. The University of Texas M. D. Anderson Cancer Center: Microarray Core Facility. Available at: http://www.mdanderson.org/departments/dnamicroarray) (Accessed June 27, 2006)
34. Kimchi E.T., Posner M.C., Park J.O., et al. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res 65 (2005) 3146-3154
35. Ihrie R.A., Reczek E., Horner J.S., et al. Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr Biol 13 (2003) 1985-1990
36. Nagy N., Brenner C., Markadieu N., et al. S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. Lab Invest 81 (2001) 599-612
37. Ji J., Zhao L., Wang X., et al. Differential expression of S100 gene family in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 130 (2004) 480-486
38. Kimos M.C., Wang S., Borkowski A., et al. Esophagin and proliferating cell nuclear antigen (PCNA) are biomarkers of human esophageal neoplastic progression. Int J Cancer 111 (2004) 415-417
39. Izzo J., Malhotra U., Wu T.T., et al. Association of activated transcription factor NF-kappaB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24 (2006) 748-754
40. Abdel-Latif M.M., O'Riordan J., Windle H.J., et al. NF-kappaB activation in esophageal adenocarcinoma: Relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 239 (2004) 491-500